{
    "ticker": "SPRU",
    "name": "Spruce Biosciences, Inc.",
    "description": "Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapies for rare endocrine disorders. Founded in 2016, Spruce is dedicated to advancing the treatment of conditions such as congenital adrenal hyperplasia (CAH) and other serious hormonal imbalances. The company's lead product candidate, Tetracosactide, is designed to provide a more effective and patient-friendly solution for individuals suffering from CAH, a condition that can lead to severe health complications if left untreated. Spruce's mission is to improve the lives of patients by delivering novel therapies that address significant unmet medical needs in the endocrine space. The company employs a patient-centric approach, working closely with healthcare providers and patients to ensure that their therapies are not only effective but also enhance the quality of life for those affected by rare diseases. With a robust pipeline and a commitment to scientific excellence, Spruce Biosciences aims to become a leader in the field of rare disease treatment, leveraging advanced research and development to bring groundbreaking therapies to market.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2016",
    "website": "https://www.sprucebiosciences.com",
    "ceo": "Ben Hwang",
    "social_media": {
        "twitter": "https://twitter.com/SpruceBiosci",
        "linkedin": "https://www.linkedin.com/company/spruce-biosciences/"
    },
    "investor_relations": "https://investors.sprucebiosciences.com",
    "key_executives": [
        {
            "name": "Ben Hwang",
            "position": "CEO"
        },
        {
            "name": "Michael A. S. L. Ho",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Tetracosactide"
            ]
        }
    ],
    "seo": {
        "meta_title": "Spruce Biosciences, Inc. | Innovating Rare Disease Therapies",
        "meta_description": "Learn about Spruce Biosciences, Inc., a biopharmaceutical company dedicated to developing innovative therapies for rare endocrine disorders. Discover our commitment to improving patient lives.",
        "keywords": [
            "Spruce Biosciences",
            "rare diseases",
            "endocrine disorders",
            "biopharmaceuticals",
            "Tetracosactide"
        ]
    },
    "faq": [
        {
            "question": "What is Spruce Biosciences known for?",
            "answer": "Spruce Biosciences is known for developing therapies for rare endocrine disorders, particularly congenital adrenal hyperplasia."
        },
        {
            "question": "Who is the CEO of Spruce Biosciences?",
            "answer": "Ben Hwang is the CEO of Spruce Biosciences, Inc."
        },
        {
            "question": "Where is Spruce Biosciences headquartered?",
            "answer": "Spruce Biosciences is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is the main product of Spruce Biosciences?",
            "answer": "The main product candidate of Spruce Biosciences is Tetracosactide."
        },
        {
            "question": "When was Spruce Biosciences founded?",
            "answer": "Spruce Biosciences was founded in 2016."
        }
    ],
    "competitors": [
        "VRTX",
        "AMGN",
        "ALNY"
    ],
    "related_stocks": [
        "GILD",
        "BMRN",
        "REGN",
        "NVS"
    ]
}